Cargando…

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer

BACKGROUND: To investigate the clinical relevance of CK-19mRNA-positive circulating tumour cells (CTCs) detected before the initiation of front-line treatment in patients with metastatic breast cancer (MBC). METHODS: The presence of CTCs was detected in 298 patients with MBC using a real-time PCR (R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Androulakis, N, Agelaki, S, Perraki, M, Apostolaki, S, Bozionelou, V, Pallis, A, Kalbakis, K, Xyrafas, A, Mavroudis, D, Georgoulias, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388568/ https://www.ncbi.nlm.nih.gov/pubmed/22669159 http://dx.doi.org/10.1038/bjc.2012.202

Ejemplares similares

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer
por: Xenidis, N, et al.
Publicado: (2013)

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse
por: Saloustros, Emmanouil, et al.
Publicado: (2011)

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status
por: Souglakos, John, et al.
Publicado: (2006)

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2022)

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer
por: Daskalaki, A, et al.
Publicado: (2009)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
por: Emmanouilides, Christos, et al.
Publicado: (2007)

Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy
por: Spiliotaki, Maria, et al.
Publicado: (2014)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2011)

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
por: Lianidou, E S, et al.
Publicado: (2013)

Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
por: Kalbakis, K, et al.
Publicado: (2001)

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
por: Papadaki, Maria A, et al.
Publicado: (2014)

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2008)

Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy
por: Papadaki, Chara, et al.
Publicado: (2020)

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
por: Saridaki, Z, et al.
Publicado: (2012)

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2015)

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study
por: Georgoulias, V, et al.
Publicado: (2005)

KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer
por: Kalikaki, Aristea, et al.
Publicado: (2014)

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer
por: Polioudaki, Hara, et al.
Publicado: (2015)

Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2009)

Expression of insulin‐like growth factor‐1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes
por: Spiliotaki, Maria, et al.
Publicado: (2017)

Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer
por: Papadaki, Maria A., et al.
Publicado: (2020)

Favorable Clinical Course of Patients Experiencing Bevacizumab-Induced Proteinuria
por: Saloustros, Emmanouil, et al.
Publicado: (2010)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Papadaki, Maria A., et al.
Publicado: (2021)

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group
por: Mavroudis, Dimitrios, et al.
Publicado: (2017)

What's new on circulating tumor cells? A meeting report
por: Lianidou, Evi S, et al.
Publicado: (2010)

Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
por: Rounis, Konstantinos, et al.
Publicado: (2023)

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
por: Greystoke, A, et al.
Publicado: (2012)

Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients
por: Agelaki, Sofia, et al.
Publicado: (2016)

A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer
por: Monastirioti, Alexia, et al.
Publicado: (2021)

Skin and Soft Tissue Infections in Patients with Solid Tumours
por: Kofteridis, Diamantis P., et al.
Publicado: (2012)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer
por: Pallis, Athanasios G, et al.
Publicado: (2010)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
por: Chimonidou, Maria, et al.
Publicado: (2017)

Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer
por: Papadaki, Chara, et al.
Publicado: (2018)

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2014)

Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer
por: Papadaki, Chara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f197avm8urpr1gpbmduahffcsp